PIP: Recently a group of hormonal contraceptives, used in the treatment of skin diseases, has been taken off the market, leading dermatologists to critically evaluate sex hormone (SH) therapy. The antiandrogenic side effect of hormonal contraceptives has been effective in treating hormonally induced skin disorders, e.g., involving oil or endocrine secretion, and hair growth. SH therapy is indicated for treatment of female acne (reports of 70% success after 2-6 months' intensive therapy), and in some cases male acne, and also for seborrhoea (report of 90% success after 1-3 months' intensive treatment), also for female sebocystamatose and Fox-Fordyce disease. In the case of female androgenic alopecia and hirsutism, SH therapy results are limited. Rosacea and periole dermatitis should probably not be treated with SH therapy. Patients with skin disorders should carefully avoid any androgen-effective oral contraceptives, even for birth control purposes, and pay particular attention to the progesterone content, since some progesterones have androgenic aftereffects (testosterone anabolica, nortestosterone derivatives). The 2-phased Eunomin with chlormadinone is 1 recommended hormonal antiandrogenic preparation available at the present time. If 1-phase therapy is preferable, Menova may be used. Since remissions of psoriasis have been observed in pregnancy, SH therapy with nortestosterone may be indicated; and also in the case of herpes simplex menstrualis and perigo simplex subacuta, therapy should be attempted.